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ABSTRACT
Measuring HPV exposure relies on detection of HPV type-specific antibodies, but
methods are not standardized. Additionally, there is little information on the best sample
type for HPV antibody detection. This study validated pseudovirion neutralization
(PVN) assay for HPV antibody detection and compared it to IgG ELISA. Both assays
were applied to paired serum and cervical mucus samples. Additionally, PVN assay was
utilized to evaluate the feasibility of oral mucosal transudate (OMT) samples to monitor
the HPV immune response. Serum was more likely to be positive on PVN assay than on
IgG ELISA (p= 0.025). Both assays correlated with HPV-16 DNA status. HPV-18 PVN
assay results correlated with HPV-18 DNA status. Few cervical mucus samples had
detectable antibodies; no correlation with HPV DNA status was seen. OMT results were
unsatisfactory. PVN assay was more sensitive than IgG ELISA; serum was a more
reliable indicator of HPV-16/18 antibody status than cervical mucus.
INDEX WORDS: Human Papillomavirus, Antibody detection, IgG ELISA,
Pseudovirion neutralization assay
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Introduction
Human papillomaviruses (HPV) are a significant public health problem. HPV is
the most common sexually transmitted infection in the United States. Each year there are
an estimated 6.2 million new HPV infections in the United States alone. It is estimated
that 75% of sexually active women will be exposed to HPV in their lifetime. While the
vast majority of infections are asymptotic and transient, persistent HPV infection is a
significant risk for anogenital neoplasia. In particular, HPV is detected in over 99% of all
cervical cancers (Walboomers, Jacobs et al. 1999). Worldwide, cervical cancer is
associated with 300,000 deaths each year. (Frazer, Cox et al. 2006; Lowy and Schiller
2006; Trottier and Franco 2006; Markowitz, Dunne et al. 2007)
Papillomaviruses are a family of closely related double-stranded DNA viruses in
the family Papillomaviridae. Papillomaviruses have been found in nearly all animals,
and maintain tight species specificity. The viral particles are 55 nm in diameter,
composed of a non-enveloped protein shell with a circular 8 kb genome (as reviewed in
Zheng and Baker 2006). The genome is similarly arranged in all papillomaviruses into
three regions: early, late, and non-coding regions. The early region encompasses over
50% of the genome and contains six or seven open reading frames (ORF) transcribed in a
polycistron message from one DNA strand. HPVs have six early ORFs coding for
proteins E1, E2, E4, E5, E6, and E7 (as reviewed in Zheng and Baker 2006). E1 and E2
are involved in regulating viral DNA replication and transcription. The E4 protein is
produced during an active infection and is associated with cytokeratin filament collapse.
Proteins E5, E6, and E7 are responsible for maintaining DNA synthesis in differentiated
cells by inactivating the tumor cell repressors p53 and pRb. This is required to allow the
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virus to efficiently replicate and complete it life cycle. However the action of these viral
proteins also contributes to DNA instability and blocked apoptosis via the same
pathways, so these proteins, particularly E6 and E7 also are the oncogenic proteins. The
late region consists of 40% of the papillomavirus genome, coding for the L1 and L2
ORFs, which are the major and minor capsid proteins of the virus respectively (as
reviewed in Zheng and Baker 2006). The non-coding region encompasses the remaining
10% of the papillomavirus genome. This non-coding region contains numerous
transcription factor binding sites that have been associated with the RNA polymerase II.
(as reviewed in Zheng and Baker 2006)
There are over 100 types of HPV; each designated a number based on the order of
their discovery. At least 40 HPV types can infect the genital area. HPVs that affect the
genital area can be divided further into subcategories of low and high risk. Low risk
types are those rarely associated with malignant lesions. These types are associated with
low grade squamous intraepithelial lesions (LSIL) of the cervix, genital warts and
recurrent respiratory papillomatosis (wart-like growths in the upper respiratory tract).
HPV 6 and 11 are responsible for the majority of the latter two lesions. High risk types
are those associated with malignancies, but these types are also most prevalent in the
general population and are associated with LSIL as well as high grade squamous
intraepithelial lesions (HSIL) of the cervix. High risk HPV types include 16, 18, 31, 33,
35, 39, 45, 51, 56, 58, 69, 73, and 82. Worldwide, types HPV 16 and 18 are detected in
70% of all cervical cancers. High risk HPV has also been linked to other cancers such as
vulvar, vaginal, penile, anal, and oropharyngeal cancer. (Frazer, Cox et al. 2006; Parkin
and Bray 2006; Trottier and Franco 2006)
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HPV is epithelioptropic, that is, infection is confined to epithelial cells. Based on
papillomavirus model systems, infection is believed to be initiated in basal cells of the
epithelium. Basal cells may be accessible to infection as a result of minor epithelial
trauma, or at squamocolumnar junctions, such as at the transformation zone of the cervix.
The basal cells are undifferentiated self-renewing cells that have stem cell-like properties.
In the basal layer of the epithelium the virus is maintained as an episome at relatively low
copy numbers (10-50 copies per cell) (Stanley 2006).
The virus is dependent on host cellular machinery for replication and
transcription. A differentiating environment is required for completion of the viral life
cycle, and high copy number viral replication is noted in differentiating keratinocytes.
This feature contributes to the inability to culture HPV in vitro. As noted above, HPV E6
and E7 prolong cellular replication in differentiated cells that would normally not be
dividing. This prolonged cell division results in a thickened epithelium, sometimes
producing a wart-like growth. The L1 and L2 genes are expressed in cells near the
epithelial surface and complete viral particles self-assemble in the nucleus. Virus is shed
in association with cells as they exfoliate from the epithelium as part of terminal
differentiation. (Stanley 2006)
The non-lytic nature of the infection and restriction of infection to the epithelial
compartment results in minimal exposure of the virus to the host immune system.
Nonetheless, both humoral and cellular immune responses can be detected. Cellular
immunity is most important for viral clearance, in particular macrophage and T cell
response directed against the HPV E2 and E6 proteins (Stanley 2006). While the innate
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immunity initiates the first response to HPV infection, seroconversion, the production of
antibodies, can take from 6 months to 1 year to occur (Carter, Koutsky et al. 2000).
Additionally, it has been noted that the number of individuals that will never seroconvert,
even though they are persistently HPV DNA positive, is less than 50 percent (Carter,
Koutsky et al. 2000; Pagliusi, Dillner et al. 2006). Thus, it is estimated that 70-80% of
those exposed have detectable antibodies to HPV (Carter, Koutsky et al. 2000; Pagliusi,
Dillner et al. 2006). Once seroconversion has occurred, antibodies levels remain
detectable for years (Scheurer, Tortolero-Luna et al. 2005). Therefore seroprevalence is a
relatively specific measure of viral exposure, but has limited sensitivity.
Based upon inoculation studies, HPV seroconversion occurs via: quick onset of
IgM and IgA response, rapid decline in IgM with a slow descent of IgA antibodies, and
finally the steady appearance of IgG antibodies (Scheurer, Tortolero-Luna et al. 2005). A
similar sequence of the IgA and IgG response is seen in cervical mucus; where presence
of IgA is associated to current HPV infection and the presence of IgG was noted to be
associated with lesion formation (Sasagawa, Rose et al. 2003; Bierl, Karem et al. 2005).
Antibody production is important for protecting against the spread of infection and reinfection. (Lowy and Schiller 2006; Stanley 2006; Trottier and Franco 2006; Markowitz,
Dunne et al. 2007)
Despite the close similarity of all the HPVs, the antibody response is typespecific. A variety of experimental and in vitro systems have demonstrated that three
dimensional conformational epitopes of papillomavirus virions are required to generate
antibodies that block binding and infection. While antibodies can be detected against
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linear peptide epitopes, only antibodies against conformational epitopes have neutralizing
properties. (Carter, Wipf et al. 2003; Orozco, Carter et al. 2005)
The L1 capsid protein, produced by recombinant protein expression systems, self
assembles into structures that resemble intact virions when examined by electron
microscopy. Because of this resemblance, the empty protein shells are called virus-like
particles (VLPs). HPV type specific VLPs are used the target antigen in direct enzymelinked immunosorbent assays (ELISA). In this format VLPs bound to ELISA plate are
used as the target for binding of antibodies in the sample. Antibodies to a specific
immunoglobulin subclass are used to bind antibodies that recognize the VLPs. The antiimmunoglobulin antibody is either conjugated to an enzyme or hapten which is used to
subsequently localize an enzyme. The enzyme localization is revealed with a
colorimetric or chemiluminescent substrate. The indirect ELISA is a variation of this
assay that uses an HPV type-specific antibody to bind the VLPs to the microtiter plate
well. The VLP ELISAs generally detect only one immunoglobulin subclass (e.g. IgG or
IgA), dependent on the specificity of the detecting antibody.
The VLP ELISA has been the gold standard for HPV antibody detection. Yet, the
VLP ELISA has several short comings. VLPs can be produced in a variety of expression
systems including insect cells, yeast and vaccinia. Each method of production requires
time consuming methods for purification of intact VLPs from the crude expression
lysates. Usually ultracentrifugation, electron microscopy and protein gel electrophoresis
are required to evaluate the VLP preps. While VLPs from each expression system would
theoretically be equivalent reagents, they do differ in the type of non-specific antigen
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carryover. VLP preparations vary between laboratories and between lots within a
laboratory.
There are no commercial VLP reagents available, therefore each laboratory must
undertake the production and quality control assays required for supplying the intact
high-qualityVLPs that are central to the specificity of the ELISA. In addition, methods
for determining the cut-off for value a positive result are not standardized and positive
and negative control samples are not available. As a result the sensitivity and specificity
of VLP ELISAs are difficult to validate. In addition, unless a form dilution series is
performed to determine the titer, the VLP ELISA does not offer a quantitative measure of
antibodies.
The competitive VLP ELISA is variation of the standard VLP ELISA assay
(Wang, Christensen et al. 1997) in which the sample to be tested competes with an HPV
type specific antibody for binding to the VLP. A variety of detection methods are
possible. The competing antibody may be directly labeled with an enzyme, fluorescent
tag or hapten, or, if produced in a different species such as mouse, detected with speciesspecific labeled antibodies. Samples that prevent the competing antibody from binding
are considered true positives. The type specificity of the assay is improved by the
competing antibody. However, particularly when monoclonal antibodies are used, some
true positive samples may fail to compete because they recognize epitopes not
represented in the competing antibody.
Recently a pseudovirion neutralization (PVN) assay was developed to evaluate
serum antibodies (Buck, Pastrana et al. 2005). Pseudovirions differ from VLPs in that
they contain DNA. In addition, like true virions, both L1 and L2 proteins are used to
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make the pseudovirion. While the minor capsid protein L2 does not significantly change
the surface epitopes, L2 is required to increase the efficiency of capturing DNA. The
DNA in a pseudovirion is released when the particle binds to a cellular surface. This
mimics the infectious process and following the DNA from the pseudovirion allows an in
vitro assessment of the first steps of the HPV infection. The recently described assay
uses secreted alkaline phosphatase (SEAP) as the reporter plasmid gene. Release of
alkaline phosphatase into the tissue culture media indicates “infection”. Antibodies that
bind to pseudovirions prevent the particles from binding to cells. These neutralizing
antibodies are type-specific and, in animal model systems, correlate with protection from
infection. Any immunoglobulin that binds to the pseudovirion is detected based on a
reduction in the SEAP in the media. Thus all neutralizing antibodies, regardless of
immunoglobulin type are detected (e.g. IgG, IgA, etc.)
There are numerous advantages to the PVN assay. The pseudovirions are
produced in cell lines transfected with expression plasmids for L1 and L2 proteins of
HPV along with the SEAP plasmid. Once the transfected cell lines are prepared, the
production of pseudovirus is more efficient than VLP production. Only type specific
neutralizing antibodies will be detected and the detection of all immunoglobulins has the
potential to improve sensitivity. Additionally, ease of pseudovirion production facilitates
assaying serum dilutions providing an antibody titer as a quantitative measure. Initial
studies indicate the PVN assay is more sensitive and specific than the ELISA (Pastrana,
Buck et al. 2004).
Theoretically, the PVN assay could be used with any sample that contains
antibodies. However to date it has only been applied to serum samples. HPV ELISA
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assays in cervical mucous are compromised by the lack of references for what would
constitute a positive reaction as well as by low titers. The PVN assay, by providing
increased sensitivity and clear criteria for a positive result, could improve the analysis of
the mucosal antibody response at the cervix.
Because the mucosal immune response is thought to be generalized, detection of
antibodies at one mucosal surface (the cervix) should be linked to antibody detection at
another mucosal surface (oral detection). Oral antibodies can be collected using
noninvasive sampling methods, and if correlated with serum and cervical response,
would have advantages for monitoring populations for exposure to HPV. Few studies
have examined oral antibodies, and to date only VLP ELISAs have been used (Marais,
Rose et al. 2000; Cameron, Snowhite et al. 2003). While HPV antibodies were detected
in oral fluids, this sample type was much less likely to be positive than the corresponding
serum sample (Marais, Rose et al. 2000).
The newly licensed vaccine against HPV has focused attention on potential
clinical and public health applications of measuring antibodies to HPV. In vaccine trials
serum antibodies are used to monitor the response to vaccination. Antibody titers seen
after vaccination are much higher than those seen in natural HPV infection (Markowitz,
Dunne et al. 2007). Currently there is no antibody correlate of protection and HPV
immunoassays are not recommended for individuals. However antibody assays may play
a role in post-vaccine surveillance in populations.
The aims of this study were to establish and validate the PVN assay for HPV 16
and 18 in serum, and to apply the assay to paired serum and cervical mucous collected in
a in a subset of high risk adolescent females enrolled in a longitudinal study of HPV and
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other sexually transmitted infections. Results of the PVN assay will be compared to the
direct VLP ELISA and known epidemiologic risk factors for HPV antibodies (such as
HPV DNA detection and number of sex partners). The assay will also be applied to oral
fluid samples collected in the same study. Results of this study will be used to determine
the optimal sample type and testing method in future studies of HPV seroprevalence and
post-vaccine surveillance studies.
Methods and Materials
Study Population and Sample Collection
The study population is a subset of those enrolled in a larger multi-objective
longitudinal study of sexually transmitted infections conducted at a public pediatric clinic
in Atlanta, Georgia (Koumans, Black et al. 2003). Sexually active females age 13-19
years were eligible to participate if a pelvic exam was indicated; participants were
excluded if pregnant or HIV infected, or treated with antibiotics in the past month.
Informed consent of the adolescent and consent of a parent/guardian or the consent of
adolescents aged 18 or 19 years was obtained prior to enrollment. At each visit a
questionnaire was administered in private by trained interviewers (Tarkowski, Koumans
et al. 2004). The questionnaire included questions on demographics, sexual and
reproductive history, condom use, drug, and alcohol use. Visits were on average six
months apart. The study was reviewed and approved by the institutional review boards at
the Centers for Disease Control and Prevention and Emory University.
At each visit, biologic samples were collected including peripheral blood,
exfoliated cervical cells, cervical mucus, and oral samples. Oral samples were only
collected as a pilot on a subset of participants. The peripheral blood was collected via
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venous puncture and allowed to clot at room temperature. Serum was aliquotted and
stored at -80 °C until use.
At the time of pelvic examination, two weck-cel sponges (Medtronic,
Minneapolis, MN) were placed into the cervical os until the sponges were saturated with
cervical mucous (at least one minute). The saturated sponges were placed into a labeled
microfuge tube and placed on dry ice until transported to the laboratory for storage at -80
°C until extraction.
After collection of the cervical mucosal sample, endo- and exo-cervical samples
were collected using the Cytyc plastic broom collection kit (Cytyc. Corporation,
Boxborough, MA) and placed in 20 ml PreservCyt cytology fixative (Cytyc. Corporation)
following manufacturer’s protocol for routine diagnostic ThinPrep Pap smear (Cytyc
Corporation). ThinPrep Pap smears were prepared and evaluated in the hospital
cytopathology laboratory. The cytologic diagnosis, based on Bethesda classification, was
recorded from the resulting clinical report. HPV detection and typing was performed on
an aliquot of residual Thin Prep using L1 consensus PCR and the Roche Prototype line
blot assay as previously described (Tarkowski et al. 2004). The HPV DNA results were
used to select subjects and samples for this study.
Oral samples were collected using the OraSure collection device (OraSure
Technologies, Bethlehem, PA). The collection pad was rubbed across the gum line twice
and then placed between along the lower gum line for 2 min. The collection pad was
then placed into a storage vial with storage buffer and centrifuged to collect the sample.
Oral samples were stored at -20 °C until use, when they were thawed and heat inactivated
at 56 °C in a water bath for 30 minutes.
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Selection of Samples for Analysis
Detection of HPV 16 or 18 DNA in the cervical sample was used to indicate
exposure. For comparison of humoral and mucosal antibody detection, all women with a
sample positive for HPV 16 or 18 were selected (exposure group) as were an equal
number of women never testing positive for these types (comparison group). The
comparison group was matched to the exposure group based on age (± 6 months), race
and number of sex partners. Serum and mucosal samples collected from an individual
within 180 days of each other were considered to be matched samples. For the exposure
group the samples had to be collected at or after the date of the positive PCR test.
Of the 312 number of women enrolled in the original study, 64 were positive for
16 or 18. Of these, 36 had serum available (24 HPV 16 positive and 12 HPV 18
positive). All but one woman also had a matched mucosal sample. Based on matching
criteria, 35 women with a serum sample were available as the comparison group, 32 of
whom had a matched mucosal sample. The dates of sample collection fell between
1/14/1999 and 12/12/05.
For detection of oral antibodies, all 299 available samples collected from 209
women were included. These samples included 23 from women positive for HPV 16 and
9 from women positive for HPV 18. Only 16 women contributed samples to both the
oral and humoral/mucosal study.
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Cervical Mucus Extraction
Tubes containing the cervical mucus sample were removed from the freezer,
placed on ice and incubated 30 minutes in 300 μl of lysis buffer (10 ml M-Per
Mammalian Protein Extraction Reagent (Pierce, Pittsburgh, PA) to which 0.9 g NaCl
(Fisher-Scientific, Pittsburgh, PA), and 1 tablet of Complete Mini, EDTA-free Protease
Inhibitor Cocktail was added(Roche, Indianapolis, IN)). The swab sticks were cut from
the pad, and each pad was placed into a Spin-X centrifuge tube (Costar, Corning, NY)
and centrifuged for 15 minutes at 16,000 X G. An additional 300 μl of lysis buffer was
added to the top of each Spin-X tube and the tubes were centrifuged as before. The
combined eluates from both spins were then aliquotted, 200 μl per tube, and stored at 80° C until use.
HPV 16 Virus Like Particle IgG Enzyme Linked Immunosorbent Assay (HPV 16 VLP IgG
ELISA)
The HPV 16 VLP IgG ELISA was performed on both serum and mucosal
samples as previously described (Karem, Poon et al. 2002). Briefly, a 96-well microtiter
plate (Fisher-Scientific, Pittsburgh, PA) was coated overnight at 4 ° C with HPV 16
VLPs (0.1 μg/well; CDC in-house preparation). The plate was washed and blocked at
room temperature. Serum and mucosal samples were diluted 1:20 and a 50 µl aliquot
was added per well. Duplicate wells on the same plate were used for each sample. After
a one hour incubation at 37° C, the plate was washed and detected 2 h at 37° C with a
1:1000 dilution of Goat Anti-Human IgG-Alkaline Phosphatase conjugate (Roche).
Following washing, signal was developed for 45 min. at room temperature with freshly
prepared substrate (Sigma 104 Alkaline Phosphatase Substrate tablets, St. Louis, MO)
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and read at 405 nm. Each plate included eight control samples (four known positive and
four known negative for HPV 16 based on blocking ELISA, described below). A single
lot of VLP was used for all assays in this study. The average value of the optical density
(OD) for duplicate wells of each sample was calculated. Serum samples with OD >
0.275, a laboratory determined cut-off value based on results with inter-laboratory control
sera were considered positive. Mucosal results were handled as OD values because
samples available for establishing a cut-off were not available.
HPV 16 Blocking Assay
A blocking Assay was utilized to select HPV 16 positive and negative sera to be
used as pooled and individual controls. The IgG VLP ELISA was performed as
described above with modifications as noted. The microtiter plate was coated with 0.5 μg
HPV 16 VLP per well and blocking buffer was changed to 2% skim milk (FisherScientific) in 1 X phosphate buffered saline Tween 20 (PBST; Cellgro, Herndon, VA)
and block performed 1.5 h at 37 ° C. Sample diluent was changed (2% skim milk, 2%
Goat Serum, 1% Insect Cell Lysate, 1 X PBST) and 50 µl volume per well was added.
After 1.5 h incubation at 37 °C, 50 µl of mouse anti-HPV 16 monoclonal antibody (gift
of Neil Christiansen, Hershey Medical Center) at two dilutions (1:100 and 1:200) were
added to replicate wells and incubated an additional 1.5 h at 37 °C. Conjugate was
changed to goat anti-mouse IgG alkaline phosphatase (Chemicon, Temecula, CA) diluted
at 1:1000 in 2% skim milk in 1 X PBST and incubation time was reduced to 1.5 hours.
The ability of the sample to block the mouse monoclonal from binding to the VLP was
calculated as [1- (OD value of Mouse Anti-16 with serum/OD value of Mouse Anti-16
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alone)] x 100% for both the1:100 and 1:200 dilutions. A value of ≥ 23% for either
dilution was considered positive.
HPV 16 VLP IgA Chemiluminescent Enzyme Linked Immunosorbent Assay (ELISA)
The IgA chemiluminescent ELISA was performed as described in the IgG ELISA
assay except the block consisted of 5% skim milk, 5% Goat Serum, 2% Bovine serum
albumin, ((BSA) Sigma) in PBST. OraSure samples were used undiluted. A goat antihuman IgA alkaline phosphatase conjugate (Calbiochem, San Diego, CA) was diluted at
1:1250 in Conjugate Diluent (2% skim milk, 1% BSA, PBST). BM Chemiluminescence
ELISA Substrate (AP) (Roche) was prepared according to manufacturer’s protocol and
50 µl was added to the plate. The plate was incubated for 10 min. and was read on the
Victor 2 Luminometer on the chemiluminescence setting.
Pseudovirion Neutralization (PVN) Assay
The assay was performed according to Pastrana, Buck et al. (2004). 293TT
human embryonic kidney cells (Invitrogen) were plated on 96-well tissue culture plates
(Costar) at 30,000 cells/ well in neutralization buffer (Dulbecco’s Modified Eagle
Medium (DMEM) without phenol red (Invitrogen), 10% heat-inactivated fetal bovine
serum (FBS; Atlas Biologicals, Fort Collins, CO), 1% glutamax (Invitrogen), 1%
nonessential amino acids (Invitrogen), 1% Hepes (pH 7.5) (Invitrogen), and 1%
penicillin-streptomycin-fungizone (Invitrogen)). Tissue culture plates were incubated for
3 h at 37 ° C.
Serum and mucosal samples were diluted 2-fold from 1:4 to1:512 in
neutralization buffer. 22 μl of sample was added to 88 μl of HPV or BPV1 pseudovirions
(PV; prepared as described below) on a 96-well microtiter plate (HPV 16 PV diluted at

15
1:200, HPV 18 PV diluted at 1:30, and BPV1 PV diluted at 1:250 in neutralization
buffer). The final sample dilutions ranged from 1:20 to 1:2560 for both serum and
mucosal samples. Oral mucosal samples were diluted at 1:2, 1:4, and 1:8 in neutralization
buffer and 22 μl of the sample was added to 88 μl of HPV 16 or BPV pseudovirion on a
96-well microtiter plate ( PV diluted as describe above in neutralization buffer). The
final dilution of oral samples was 1:5, 1:10, and 1:20.
HPV 16 pseudovirion plate positive controls consisted of pooled HPV 16 positive
sera (in house samples verified on HPV 16 blocking assay) diluted at 1:180, and heparin
(Sigma), diluted at 1 mg/ml. The plate positive control for HPV 18 consisted of a mouse
anti-18 monoclonal antibody, 5074 (Dr. John Schiller, NIH), and a mouse anti-16
antibody (Dr. John Schiller, NIH) diluted at 1:20 was utilized as a negative control. The
plate positive control for BPV1 consisted of mouse anti-BPV 1 monoclonal 5B6 (Dr.
John Schiller, NIH) diluted at 1:20,000. Plate negative controls consisted of pooled HPV
16 negative sera (in house samples) diluted at 1:540, neutralization buffer, and Antipapillomavirus mouse monoclonal ( types 6, 11, and 18; Novocastra Laboratories Ltd,
Tyne, United Kingdom) diluted at 1:100 for HPV 16, HPV 18 and BPV1 pseudovirion
stocks. 2 2μl of each control was added to 88 μl of HPV or BPV1 pseudovirion and was
added to the 96-well microtiter plate. Samples and controls were incubated 1 h. with
pseudovirions on ice, and 100 μl of each mixture was then added to the cells and cultured
for 72 hours at 37 °C in a 5% CO2 tissue culture incubator.
A 50 μl aliquot of the cell supernatant was transferred into a 96-well roundbottom microtiter plate (Costar) and incubated with 150 μl of Tris buffered saline (25mM
Tris HCl, 150mM NaCl, pH 7.4; TBS) 30 min. at 65 °C. After incubation, plates were
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centrifuged for 5 min. at 3000 rpm and placed on ice for 5 min. A 50 μl aliquot of the
supernatant was transferred to a white chemiluminescent microtiter plate (Dynex,
Chantilly, VA) and assayed for SEAP activity by adding 100 μl of BM
Chemiluminescence ELISA Substrate (AP) (Roche, prepared as kit indicated), covering
with an aluma-seal II plate cover (Excel Scientific, Wrightwood, CA) and incubating
with shaking 10 min. at room temperature. Plates were read on the Victor 2
Luminometer set at glow-endpoint 0.20 sec/well.
Preparation of L1, L2, and SEAP Plasmids for Pseudovirion Production
Recombinant plasmids (p16L1h, p16L2h, peL1fb, peL2bhb, pSheLL, pYSEAP;
all received as a gift from John Schiller, NIH) were used to transform DH5-α competent
E.coli cells (Invitrogen) as recommended by vendor. Transformed clones were selected
based on antibiotic resistance gene carried in the plasmid and used to prepare a 3 ml
overnight culture. Bacteria were lysed using detergent and boiling, and plasmid DNA
extracted using the Qiagen HiSpeed Maxi Kit (Qiagen, Valencia, CA) according to the
manufacturer’s protocol. Plasmid DNA was resuspended in 1 ml of ddH2O and
concentration was determined by absorbance at A260.
To verify plasmid composition, PCR was performed.
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Table 1. Sense and anti-sense primers utilized for PCR according to the plasmid being
amplified.
Insert/
Plasmid
16 L1
p16L1h
16 L2
p16L2h
18 L1
peL1fb
18 L2
pL2bhb
BPVL1
pSheLL
BPVL2
pSheLL
SEAP
pYSEAP

Primer sequence (5’-3’)
F-16L1/L2-920- AGGCCTGTACGGAAGTGTTAC
R-16L1-2576 – ACAGATGGCTGGCAACTAGA
F-16L1-1182- GGTGAGCGGCCTGCAGTACAG
R-16L1-2353 – GTCCAGGTCGGCGCTGAA
F-16L1/L2-920 - same as above
Reverse primer same as above (R-16L1-2576)
F-16L2-1001-AGAGGAGCGCCAAGAGGACCAAG
R-16L2-2385 – GCCAGGCTCACGTCGCTGAAG
F-18L1-785- CTAAAAGCTGCGGAATTGT
R-18L1/L2 – TTCACTGCATTCTAGTTGTGG
F-18L2-717 - CCTTGGAGCCTACCTAGACT
R-18L1/L2 – same as above
F-BPVL1-600- ACCGGACTCAGATCTCGAGAA
R-BPVL1-2134- CGCGGTACCGTCGACTCTA
F-BPVL2-2567 - CCTCAAGCGTATTCAACA
R-BPVL2-4469 – TTTAATAGTGGACTCTTGTTC
F-BPVL2-3181 - GTCCATCGGCACAGACTCCTC
F-SEAP-1683- GATCTGCGATCTAAGTAAGC
R-SEAP-3391- TGTTAACTTGTTTATTGCAGC

Primer
length
21
20
21
18
21
20
23
21
19
21
20
21
21
19
18
21
21
20
21

Tm
(°C)
66.7
67.0
76.0
74.5
66.7
67.0
77.5
78.0
64.2
64.9
63.7
64.9
69.8
70.8
58.0
57.3
68.7
60.4
61.8

Amplicon
size (bp)
1675
1189
1580
1404
1611
1579
1553
1923
1729

Amplicon size was verified by gel electrophoresis and restriction enzyme
digestion. 5 μl of each amplicon, digested and undigested, was loaded into a 0.8% E-gel
(Invitrogen) along with a DNA size standard. Gel was visualized under a UV light and
compared to the DNA size standard.
Pseudovirion production. Pseudovirions were produced by transfecting 293FT
(Invitrogen) cells with plasmids coding for capsids (HPV 16 L1 and L2 for HPV 16,
HPV 18 L1 and HPV 18 L2 for HPV 18, and BPV L1 for BPV1 respectively) as
described by Buck, Pastrana et al. (2004). Briefly, 293 FT cells were pre-plated in
complete media without Geneticin (Invitrogen) or antibiotic-antimycotic in a 162 cm²
flask (Corning) at 18 million cells per flask and incubated overnight at 37 °C with a
humidified atmosphere of 5% CO2. Cells were transfected with a total of 75 μg plasmid
mix per T-162 cm² flask of 5% CO2 for 4-6 h at 37 °C in CO2 incubator. [The plasmid
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mix was composed of equal parts of each required plasmid (25 μg each if three plasmids;
37.5 μg each if two plasmids) in Lipofectamine 2000 (Invitrogen).] The media was then
replaced with 30 ml of fresh complete media without antibiotics and cells were incubated
overnight. Cells were then split into a T-225 cm² flask (Corning) and cultured overnight
in fresh media without antibiotics. The media from the flask was then removed. The
cells were gently removed with trypsin and collected (Invitrogen). The media/trypsin
mix was centrifuged at 800 rpm for 7 min. at 4 °C. All but 5 ml of the supernatant was
discarded and the cells were resuspended in DPBS and centrifuged again as described
above. DPBS was discarded and the cell pellet resuspended in lysis buffer (DPBS
supplemented with 9.5mM MgCl2, 0.025% Brij-58 (Sigma), 1% Benzonase (Sigma), and
0.1% Plasmid Safe ATP Dependent DNase (Epicentre, Madison, WI)) at 100 million
cells per ml. The lysate was incubated at 37 °C for 24 h. Beckman polyallomer tubes
(Beckman Coulter, Fullerton, CA) were prepared with an Optiprep (Sigma) gradient and
the gradient was allowed to diffuse for 1.5 h. The cell lysate was chilled on ice for 10
min. A 0.17 volume of 5 M NaCl was added to chilled lysate and the mixture was iced
for 10 min. The lysate was centrifuged at 4600 rpm for 15 min. at 4 °C. The supernatant
was transferred to the top of the Optiprep tubes using siliconized tips (Bio Plastics INC)
and centrifuged for 3.5 h. at 50,000 rpm. Fractions were dripped into siliconized
microcentrifuge tubes (Bio Plastics INC). 10 μl of each fraction was run on SDS-Page
(BioRad, Hercules, CA) to determine which fraction contained pseudovirion. Fractions
containing pseudovirion were frozen at -80 °C until a titration assay was run on them to
determine fraction concentration of pseudovirion.
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Protein Assay
Total protein content of mucosal samples was determined using Coomassie Plus
kit (Pierce) as per manufacturer’s protocol. Bovine Serum Albumin Standard (BSA)
(Pierce) was diluted in PBS to obtain the final concentrations of standard: 25, 20, 15, 10,
5, and 2.5 μg/ml. A blank was also run, containing only PBS. Mucosal samples were
thawed on ice and then diluted at 1:50 in PBS. 150 μl of each standard and each sample
was placed on microtiter plate; all samples were run in duplicate. 150 μl of Coomassie
Plus Protein Assay Reagent (Pierce) was added to each well and the plate was mixed by
hand for 30 sec. The microtiter plate was then incubated at room temperature for 10 min.
and the absorbance was measured at 570 nm using the Victor 2 Luminometer. A
standard curve was plotted based on BSA standards in order to determine protein
concentrations of each mucosal sample.
Data Analysis
All data was analyzed utilizing Microsoft Office (Microsoft Corporation, Seattle,
WA), SPSS 14.0 for Windows (SPSS INC, Chicago, IL), and SAS 9.1.3 for Window
(SAS Institute INC, Cary, NC) software. Standard curves, averages, standard deviations,
absorbance, and chemiluminescence were determined using Microsoft Excel.
McNemar’s Test determined the disparity between the discordant and the concordant
PVN assay/ELISA results and was calculated using Microsoft Excel. Fisher’s Exact Test
determined the possible relationships between the PVN assay titers and HPV DNA status,
the ELISA OD values and HPV DNA status, and the PVN titers and ELISA ODs; these
were calculated via Simple Interactive Statistical Analysis website
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(http://home.clara.net/sisa/). Kappa Test (Landis and Koch 1977) showed the strength of
correlation between PVN assay’s and ELISA assay’s HPV antibody detection. Spearman
correlation coefficient looked into the PVN assay titer and ELISA OD relationship as
well as the serum and mucosal titer relationship. Both Kappa Test and Spearman
correlation were determined using SPSS. Epidemiological data was analyzed in the form
of odds ratios via SAS to determine if risk behaviors were associated with HPV infection.
Results
Study Population
The mean age of the 71 women in this study was 16.3 years (range, 13 -19 years);
66 (93%) were African American. They had been sexually active a median of 2 years
(range 0 – 5 years) and had a median of 4 lifetime sex partners (range, 1-30 partners).
Thirty three (47%) of the women had ever douched. Smoking was common in this
group; 23 (32%) smoked marijuana in the last 90 days, and 11 (15.5%) smoked tobacco
in the last 90 days. A summary of HPV DNA status for this group of women is in
provided in Tables 1 and 1A.
Serum Samples
HPV 16 antibodies. The HPV 16 pseudovirion neutralization (PVN) assay detected the
presence of HPV 16 antibodies in 41 of the serum samples (57.7%). Positive titers
ranged from 40 to 2560. Seropositive women were significantly more likely to be HPV
16 DNA positive than seronegative women (19/41, 46% versus 5/30, 16.7%; p = 0.006).
The HPV 16 IgG ELISA detected the presence HPV 16 antibodies in 15 of the
serum sample (21.1%). Seropositive women were significantly more likely to be HPV 16
DNA positive than seronegative women (9/15, 60% versus 15/56, 26.8%; p = 0.015).
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The results of HPV 16 antibody detection in serum by the PVN assay and the
HPV 16 IgG ELISA (Table 2) showed a fair correlation (κ = 0.328). The PVN assay was
significantly more likely to be positive than the IgG ELISA (p = 0.025). All IgG ELISA
positive samples were also positive in the PVN neutralization assay. The PVN
neutralization titers also showed a significant correlation with the IgG ELISA optical
density (OD) value (Figure 1; p = 0.01).
The average PVN titer of concordant positive samples (PVN+/ELISA+) was
significantly different from the discordant positive samples (PVN+/ELISA-); (1536
versus 115; p = 0.001). While fewer women with concordant positive results were HPV
16 DNA positive than those with discordant positive results (9/15, 60% versus 10/26,
38.5%), the difference was not statistically significant. However, women with a positive
serum sample by either or both assays (concordant and discordant positive) were
significantly more likely to be HPV 16 DNA positive than seronegative women (PVN/ELISA-) (5/30, 16.7%; p = 0.004 and 0.046 respectively).
HPV 18 antibodies. The HPV 18 PVN assay detected HPV 18 antibodies in 17
(23.9%) samples. Positive titers ranged from 40 to 2560. Seropositive women were
significantly more likely to be HPV 18 DNA positive than seronegative women (6/12,
50% versus 11/59, 18.6%; p = 0.05).
Cervical Mucus Samples
The mean protein concentration of the mucosal samples was 803 ± 443 µg/ml
(range 117-1847). No attempt was made to control for this difference in protein
concentration.
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HPV 16 Antibodies. The HPV 16 PVN assay detected HPV 16 antibodies in 6/67,
(8.9%) mucous samples. Positive titers ranged from 20 to 40. Mucosal positive women
were not more likely to be HPV 16 DNA positive than mucosal negative women (3/6,
50% versus 20/61, 32.7%; p = 0.23).
The cut-off value for a positive result in the HPV IgG ELISA has not been
established for mucosal samples. However, the PVN titer showed a significant
correlation with the IgG ELISA OD (Figure 2; p = 0.05). But, the mean OD for the PVN
positive samples was not significantly higher than the PVN negative samples (0.16 versus
0.15).
HPV 18 Antibodies. The HPV 18 PVN assay detected HPV 18 antibody titers in

2/67 (2.9%) samples. Positive titers range from 20 to 160. Mucosal positive women
were not more likely to be HPV 18 DNA positive than mucosal negative women (1/2,
50% versus 11/65, 16.9%; p = 0.13).
Epidemiological Associations with Immune Assays
Risk factors significantly associated with HPV 16/18 infection based on the serum
samples (Table 3 and Table 4) were lifetime number of 2-3 (p = 0.03) and ≥ 8 (p =
0.03)sex partners, HPV 16 DNA status (p = 0.01), and HPV 18 DNA status (p = 0.03).
No risk factors were significantly associated with HPV 16/18 infection based upon the
cervical mucus samples (Table 5 and Table 6).
Comparison of Serum and Mucosal Samples
Paired serum and mucosal samples were available from 67 women, allowing
direct comparison of humoral and local antibody response.
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HPV 16 Antibodies. While there was a correlation between HPV 16 PVN titers in
serum and mucosal samples (Figure 3; p = 0.01), the positive results of each assay
correlated poorly (Table 7, κ = 0.079). Serum samples were significantly more likely to
be positive than mucosal samples (p = 0.025, ± 5.02). Women with HPV 16 PVN
detectable antibodies in both serum and mucous samples were not more likely to be HPV
16 DNA positive than those negative in both assays (2/5, 40% versus 4/27, 14%, p =
0.19)
HPV 18 Antibodies. There was no correlation seen between the HPV 18 PVN
titers in serum and mucosal samples (Figure 4). The positive results of each assay
correlated poorly (Table 8, κ = 0.055). Serum samples were significantly more likely to
be positive than mucosal samples (p = 0.025, ± 5.02). Women with HPV 18 PVN
detectable antibodies in both serum and mucous samples were not more likely to be HPV
18 DNA positive than those negative in both assays (1/2, 50% versus 6/49, 12%, p =
0.14)
Oral Samples
The HPV 16 pseudovirion neutralization assay detected HPV 16 antibodies in 11
(5.3%) samples from 209 women. Of the 16 women with serum and/or mucosal samples,
2 had a positive oral sample. None of these women also had detectable antibodies in
their serum or cervical mucous samples. The OD of the HPV 16 IgA ELISA and PVN
titers showed an inverse correlation (Figure 5; p = 0.01).
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Table 2. HPV DNA status for study population.
Total
Exposure Comparison
Study
Population
Group
Group
HPV Status
[N= 35]
[N=36]
[N=71]
Negative (%)
0 (0)
19 (52.8)
19
Single Type (%)
10 (28.6)
11 (30.5)
21
Multiple Types (%)*
25 (71.4)
6 (16.7)
31
*The number of types ranged from 2-7, mean = 3.2

Table 2A. HPV DNA status for study population.

HPV Status
Neg (%)
High Risk (%)
Low Risk Only (%)

Exposure
Group
[N= 35]
0 (0)
35 (100)
0 (0)

Comparison
Group
[N=36]
19 (52.8)
12 (33.3)
5 (13.9)

Total
Study
Population
[N=71]
19
47
5

Table 3. Comparison of HPV 16 antibody detection with the IgG ELISA and
pseudovirion neutralization assay in serum.
HPV 16

PVN Assay +

PVN Assay -

ELISA +

15

0

ELISA -

26

30

25

Table 4. Univariate analysis of risk factors for detection of HPV 16/18 serum antibodies
in a subset of high risk females (n = 70).
Characteristic
Age
≤15
16
≥ 17
Age of 1st Sex
<14
14
15
≥16
Lifetime Number of Sex
Partners
1
2-3
4-7
≥8
Marijuana use in last 90 days
Yes
No
Smoking in last 90 days
Yes
No
Douching in last 90 days
Yes
No

Total
(n)

PVN+ 16/18, no.
(%)

OR (95% CI)

P

7
22
33

0 (46.7)
12 (54.5)
23 (69.7)

Reference
1.37 (0.37 - 5.1)
2.6 (0.75 - 9.2)

0.63
0.13

21
19
20
10

13 (61.9)
11 (57.9)
11 (55)
7 (70)

Reference
1.08 (0.31 - 3.9)
0.85 (0.25 - 2.8)
1.6 (0.33 - 7.9)

0.89
0.78
0.55

9
17
30
14

2 (22.2)
12 (70.6)
18 (60)
10 (71.4)

Reference
8.4 (1.3 - 55.4)
5.3 (0.93 - 29.7)
8.8 (1.2 - 61.7)

0.03
0.06
0.03

23
47

12 (52.2)
30 (63.8)

0.62 (0.23 - 1.7)
Reference

0.35

11
59

5 (45.5)
37 (62.7)

0.50 (0.14 - 1.8)
Reference

0.29

33
36

23(69.7)
18 (50)

2.3 (0.85 - 6.2)
Reference

0.10

Table 5. Univariate analysis of HPV 16 and HPV 18 DNA status for detection of HPV
16 and 18 serum antibodies in a subset of high risk females (n = 71).
Characteristic
DNA Status HPV 16 ONLY
+
DNA Status HPV 18 ONLY
+
-

Total
(n)
24
47
12
59

PVN+ 16 no. (%)

OR (95% CI)

P

19 (79.2)
22 (46.8)
PVN+ 18 no. (%)
6 (50)
11 (18.6)

4.3 (1.4 - 13.5)
Reference

0.01

4.4 (1.2 - 16.1)
Reference

0.03
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Table 6. Univariate analysis of risk factors for detection of HPV 16/18 mucosal
antibodies in a subset of high risk females (n = 66).
Characteristic
Age
≤15
16
≥ 17
Age of 1st Sex
<14
14
15
≥16
Lifetime Number of Sex
Partners
1-3
4-7
≥8
Marijuana use in last 90 days
Yes
No
Smoking in last 90 days
Yes
No
Douching in last 90 days
Yes
No

Total
(n)

PVN+ 16/18, no.
(%)

OR (95% CI)

P

4
19
32

1 (6.7)
2 (10.5)
4 (12.5)

Reference
1.6 (0.14 - 20.1)
2.0 ( 0.20 - 19.6)

0.69
0.55

21
18
19
8

1 (4.8)
2 (11.1)
1 (5.3)
2 (25)

Reference
0.75 (0.1 -5.9)
1.8 (0.15 - 21.6)
0.3 (0.04 - 2.6)

0.79
0.64
0.28

22
28
16

2 (9.1)
3 (10.7)
2 (12.5)

Reference
1.2 (0.18 - 7.9)
1.4 (0.18 - 11.4)

0.84
0.73

19
47

2 (10.5)
5 (10.6)

0.98 (0.18 - 5.6)
Reference

0.98

9
57

1 (11.1)
6 (10.5)

1.1 (0.11 - 10.0)
Reference

0.95

33
32

4 (12.1)
3 (9.4)

1.3 (0.27 - 6.5)
Reference

0.72

Table 7. Univariate analysis of HPV 16 and HPV 18 DNA status for detection of HPV
16 and 18 mucosal antibodies in a subset of high risk females (n = 67).
Characteristic
DNA Status HPV 16 ONLY
+
DNA Status HPV 18 ONLY
+
-

Total
(n)
23
44
12
55

PVN+ 16, no. (%)

OR (95% CI)

P

3 (13)
3 (6.8)
PVN+ 18, no. (%)
1 (8.3)
1 (1.8)

2.1 (0.38 - 11.1)
Reference

0.40

4.9 (0.29 - 84.6)
Reference

0.27
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Table 8. Comparison of HPV 16 antibody detection in matched serum and mucosal
samples run on HPV 16 pseudovirion neutralization assay.
HPV 16
PVN Mucosal +
PVN Mucosal -

PVN Serum +
5
34

PVN Serum 1
27

Table 9. Comparison of HPV 18 antibody detection in matched serum and mucosal
samples run on HPV 18 pseudovirion neutralization assay.
HPV 18
PVN Mucosal +
PVN Mucosal -

PVN Serum +
1
16

PVN Serum 1
49
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Serum HPV 16 ELISA vs. HPV 16 Pseudovirion Assay
1.40

ELISA OD @ 405nm

1.20
1.00
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0.40
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0.00
0
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2500

Pseudovirion Titer

Figure 1. Comparison of ELISA OD value vs. pseudovirion neutralization assay
titer of serum samples.
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Mucosal HPV 16 IgG ELISA vs. HPV 16 Pseudovirion Assay
0.18

ELISA OD @ 405nm

0.17
0.16
0.15
0.14
0.13
0.12
0.11
0.1
0

5

10

15

20

25

30

35

40

45

Pseudovirion Titer

Figure 2. Comparison of IgG ELISA OD vs. pseudovirion neutralization assay titer
in mucosal samples.
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Mucosal Titer vs. Serum Titer on HPV 16 Pseudovirion Neutralization Assay
45
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Mucosal Titer
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5
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0
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1500

2000

2500

3000
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Figure 3. Comparison of mucosal titer and serum titer on HPV 16 pseudovirion
neutralization assay.
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Mucosal Titer vs. Serum Titer on HPV 18 Pseudovirion Neutralization Assay
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Figure 4. Comparison of mucosal titer and serum titer on HPV 18 pseudovirion
neutralization assay.
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ORASURE HPV 16 IgA ELISA OD vs. HPV 16 Pseudovirion Neutralization Assay
Titer
1.60E+07
1.40E+07

IgA ELISA OD

1.20E+07
1.00E+07
8.00E+06
6.00E+06
4.00E+06
2.00E+06
0.00E+00
0

5

10

15

20

Pseudovirion Titer

Figure 5. Comparison of HPV 16 IgA ELISA OD and HPV 16 pseudovirion
neutralization assay titer in oral samples.
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Discussion
This is one of the largest studies to compare the results of serum antibody
detection using the PVN assay with the IgG VLP ELISA and the first to apply the same
comparison to cervical mucosal samples. This study design thus allows for the direct
comparison of two assay platforms as well an investigation of both the local and humoral
immune response. In addition, both assays were applied to oral fluid samples to
determine if this non-invasively collected sample would be an accurate reflection of
serum antibodies, and thus suitable for population monitoring.
While the serum PVN has been published, this assay requires considerable
technical time and expertise to establish in a laboratory. The CDC laboratory received
the required constructs and training from Dr. Schiller’s laboratory and had established the
assay for serum samples. The first part of my thesis project was to establish and validate
the assay in cervical mucous samples, an application not previously described. The
validity of the serum and mucosal PVN assays in my hands was established based on
expected performance with QC samples, controls for non-specificity (BPV PVN controls)
and results in dilution series.
In this study of 71 serum samples, detection of HPV 16 antibodies the HPV 16
PVN assay was more sensitive and specific than the HPV 16 IgG VLP ELISA; as all
ELISA positive samples were PVN positive and the ELISA assay failed to detect
antibodies in 26 PVN positive samples. This is in basic agreement with a previous study
(Pastrana, Buck et al. 2004), although the absence of ELISA+/PVN- negative samples is
somewhat unexpected. Differences in the assay format account for some of the
discrepancy. The PVN assay is able to detect total immunoglobulin from both recent
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(IgM, IgA) and past (IgG) HPV 16 infections, while the ELISA detects only IgG.
Additionally, the ELISA assay may recognize non-neutralizing and cross-reactive
antibodies not detected in the PVN assay. As the samples tested are derived from a
young population, there may be an unusually high number of recent exposures that
explains the particular advantage of the PVN assay. The validity of the PVN assay for
HPV 16 and 18 is supported by the epidemiologic association with sexual exposure
(lifetime numbers of sex partners) and HPV DNA status.
Establishing the cut-off value is a particular vulnerability of the ELISA format. In
the absence of known controls, obtained primarily based on known epidemiologic status
(such as samples from virgins with unlikely exposure to HPV, or HPV DNA positive) or
verified by an independent assay, a cut-off value cannot be established. This was the
case for the HPV 16 ELISA in cervical mucous. To compare HPV 16 antibody detection
in cervical mucus via IgG VLP ELISA and the PVN assay, only the correlation of ELISA
OD and PVN titer could be made. While there was a significant correlation, few samples
were positive in the PVN assay and there was no difference in the ELISA ODs of the
positive and negative group. Likewise there were few mucosal samples positive in the
HPV 18 PVN assay. As anticipated based on these limitations of the mucosal assays, the
HPV 16 and 18 PVN assays in matched serum and mucosal samples were poorly
correlated. In addition, unlike results with the serum assays, the mucosal antibody assays
did not correlate with HPV DNA status. The relative lack of success with the mucosal
samples may be due to using the same dilution as that used for the serum samples. If
titers are significantly lower in cervical mucous, the starting dilution may have prevented
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accurate detection. Future studies should examine less dilute mucous samples in order to
provide more definite results.
As expected, while there was a correlation between a woman’s HPV DNA status
and serum PVN assay antibody results both in terms of titers and positive reactions,
exceptions were noted. It has been noted previously that antibodies to HPV 16/18
infection can persist although the virus itself has been cleared (Pastrana, Buck et al. 2004;
Einstein, Studentsov et al. 2007). Thus, even though a woman may have tested HPV
16/18 DNA negative, she may have been previously exposed to HPV and seroconverted.
In addition, not all exposed women develop antibodies.
Results of antibody testing in the oral samples were disappointing. The PVN
assay for HPV 16 was positive in only 5.3% of the oral samples. This low detection of
oral antibodies versus serum antibodies correlates with other studies (Marais, Rose et al.
2000; Cameron, Snowhite et al. 2003). However, the inverse correlation of HPV 16
PVN titers with ELISA OD in these samples suggests the possibility of a non-specific
substance reacting with the HPV 16 pseudovirus. This was also the case with the oral
HPV 18 PVN assay (data not shown); even after heat inactivation of the oral samples, the
positive antibody reaction could not be diluted out. This non-specific substance could be
a component of the proprietary OraSure collection fluid, or occur as a result of
deterioration due to long term freezer storage in this media. The PVN assay may be
successful if alternative collection methods, similar to those used in the studies cited
above, were used. In future studies a new set of oral samples should be collected and run
on a competitive assay in addition to PVN assay.
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This study demonstrates a favorable comparison between the results of the PVN
assay and the VLP ELISA in both serum and mucosal samples. This is in part due to
ability to definitively establish a positive result based on neutralization. The improved
sensitivity of the PVN versus ELISA may not be generalizable to all populations, as the
study focused on a unique population of young highly exposed women. In this study
serum was a more reliable indicator of HPV 16 and HPV 18 antibody status than cervical
mucus or oral samples. Improvements in assay conditions, specifically less dilute
samples and alternative collection methods may improve results. Because oral samples
would represent a convenient sample for epidemiologic monitoring of HPV vaccine
uptake in the population, this sample is worth further exploration. As vaccination
produces significantly higher titers than those that occur with natural exposure, the lower
sensitivity of oral sampling may be overcome.
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